Abstracts tagged "axial spondyloarthritis and interleukins (IL)"

Abstract Number: 2729 • 2019 ACR/ARP Annual Meeting
Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial
Atul Deodhar¹, Désirée van der Heijde ², Lianne Gensler ³, Tae-Hwan Kim ⁴, Walter P. Maksymowych ⁵, Mikkel Østergaard ⁶, Denis Poddubnyy ⁷, Helena Marzo-Ortega ⁸, Louis Bessette ⁹, Tetsuya Tomita ¹⁰, Gaia Gallo ¹¹, David Adams ¹¹, Ann Leung ¹², Fangyi Zhao ¹¹, Maja Hojnik ¹¹, Hilde Carlier ¹³ and Joachim Sieper ¹⁴, ¹Oregon Health & Science University, Portland, OR, ²Leiden University Medical Center, Leiden, Netherlands, ³University San Francisco California, San Francisco, CA, ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁸NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ⁹Laval University, Quebec City, QC, Canada, ¹⁰Osaka University Graduate School of Medicine, Osaka, Japan, ¹¹Eli Lilly and Company, Indianapolis, IN, ¹²Syneos Health, Raleigh, NC, ¹³Eli Lilly and Company, Indianapolis, ¹⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Ixekizumab (IXE), a high affinity IL-17A monoclonal antibody, previously showed efficacy in AS/radiographic-axSpA1,2. COAST-X (NCT02757352) is a phase 3 study that assessed efficacy and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].